Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
schizophrenia
Biotech
MapLight turns off preclinical tap to fund schizophrenia drug
Despite mixed results for its experimental schizophrenia treatment, MapLight is going all-in on the asset—at the expense of its preclinical programs.
James Waldron
Aug 14, 2026 4:38am
MapLight shares sink on mixed ph. 2 schizophrenia readout
Jul 27, 2026 11:37am
FDA hits Newron schizophrenia ph. 3 trial with hold after death
Apr 29, 2026 2:50pm
Tortugas comes out of shell with $106M, 4 ph. 2-stage neuro meds
Apr 21, 2026 10:41am
Alto halts work on PDE4 inhibitor after ph. 2 schizophrenia fail
Apr 2, 2026 7:17am
Boehringer cuts ties to Nxera's phase 2-ready schizophrenia drug
Dec 19, 2025 6:35am
